Revelation Biosciences, Inc. Common Stock
$0.92
$0.01 (+1.05%)
$0.92Day Range$0.97
Key Statistics
Market Cap
$3.66M
Shares Outstanding
4.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 11, 2022
Round Lot
100
Locale
US
Trading Data
Day Open
$0.97
Day High
$0.97
Day Low
$0.92
Volume
15.6K
VWAP
$0.94
Prev Close
$0.91
Transactions
--
Acc. Volume
--
About Revelation Biosciences, Inc. Common Stock
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
PHARMACEUTICAL PREPARATIONSSIC 28349 employees4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO, CA, 92122650-800-3717IPO Jan 11, 2022US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001810560
- Composite FIGI
- BBG00WH4GBZ2
- Share Class FIGI
- BBG00WH4GC08
- Ticker Root
- REVB
- SIC Code
- 2834
About Revelation Biosciences, Inc. Common Stock (REVB) Stock
Revelation Biosciences, Inc. Common Stock (REVB) closed the 2026-09-16 session at $0.92, up 1.05% versus the previous close (+0.01). The stock opened at $0.97 and traded between $0.92 and $0.97 during that session. Session trading volume was 16K shares. The volume-weighted average price (VWAP) is $0.94.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Revelation Biosciences, Inc. Common Stock has a market capitalization of $3.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. REVB is listed on the XNAS exchange. The company employs approximately 9 people. Revelation Biosciences, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2022-01-11.
On this page you can find market REVB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.